EP1965783B1 - Treatment of type 2 diabetes with a combination of dpiv inhibitor and metformin or thiazolidinedione - Google Patents

Treatment of type 2 diabetes with a combination of dpiv inhibitor and metformin or thiazolidinedione Download PDF

Info

Publication number
EP1965783B1
EP1965783B1 EP06820700.0A EP06820700A EP1965783B1 EP 1965783 B1 EP1965783 B1 EP 1965783B1 EP 06820700 A EP06820700 A EP 06820700A EP 1965783 B1 EP1965783 B1 EP 1965783B1
Authority
EP
European Patent Office
Prior art keywords
combination
metformin
thiazolidinedione
dpiv inhibitor
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
EP06820700.0A
Other languages
German (de)
French (fr)
Other versions
EP1965783A1 (en
Inventor
Jonathan Rachman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Royalty Pharma Collection Trust
Original Assignee
Royalty Pharma Collection Trust
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35841111&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1965783(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Royalty Pharma Collection Trust filed Critical Royalty Pharma Collection Trust
Priority to PL06820700T priority Critical patent/PL1965783T3/en
Priority to SI200631633T priority patent/SI1965783T1/en
Publication of EP1965783A1 publication Critical patent/EP1965783A1/en
Application granted granted Critical
Publication of EP1965783B1 publication Critical patent/EP1965783B1/en
Priority to CY20131100773T priority patent/CY1114401T1/en
Revoked legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Definitions

  • This invention relates to a combination of a DPIV inhibitor and metformin or thiazolidinedione for use in a therapeutic method for glycaemic control, in particular a method for the treatment of type 2 diabetes.
  • Diabetes mellitus is a chronic metabolic disorder characterized by the presence of hyperglycaemia (raised blood glucose concentrations). It may be divided into four general subclasses, including i) type 1 or insulin-dependent diabetes mellitus (IDDM) (caused by beta-cell destruction and characterized by absolute insulin deficiency), ii) type 2 or non-insulin-dependent diabetes mellitus (NIDDM) (characterized by impaired insulin action and impaired insulin secretion), iii) other specific types of diabetes (associated with various identifiable clinical conditions or syndromes such as genetic defects of beta-cell function e.g. maturity-onset diabetes of the young types 1 - 3 and point mutations in mitochondrial DNA), and iv) gestational diabetes mellitus.
  • IDDM insulin-dependent diabetes mellitus
  • NIDDM non-insulin-dependent diabetes mellitus
  • other specific types of diabetes associated with various identifiable clinical conditions or syndromes such as genetic defects of beta-cell function e.g. maturity-onset diabetes of the young types 1
  • the prevalence of type 2 diabetes is high and is growing at an alarming rate.
  • the global burden of diabetes mellitus is expected to reach 300 million by the year 2025, with more than 90% of these individuals having type 2 diabetes.
  • the predominant pathophysiological defects leading to hyperglycaemia in type 2 diabetes are impaired insulin action (insulin resistance) and impaired insulin secretion (beta-cell dysfunction). Treating hyperglycaemia is therapeutically important in diabetes mellitus in order to prevent symptoms caused by the raised blood glucose concentrations, such as polyuria (excessive urination) and polydipsia (excessive thirst), and to reduce the risk of diabetic complications.
  • the chronic hyperglycaemia of diabetes mellitus is associated with significant, often devastating long-term complications in the eyes, kidneys, nerves and blood vessels.
  • metformin acts by decreasing glucose output from the liver, it is associated with gastrointestinal side-effects in many patients and has no impact on the decline in beta-cell function with time.
  • the sulphonylureas act by increasing insulin secretion, are associated with the side effects of weight gain and hypoglycaemia (low blood glucose concentrations) and, like metformin, have no impact on the decline in beta-cell function with time (see UKPDS).
  • the TZDs act as insulin sensitizers and, whilst they are the only class of oral agent currently licensed to treat type 2 diabetes which decreases the rate of decline of beta-cell function with time, they are associated with the side effects of weight gain and oedema.
  • DPIV inhibitors may be useful for the treatment of impaired glucose tolerance and diabetes mellitus, see International Patent Application No. WO97/40832 .
  • Clinical data suggest that the glucose lowering that occurs in response to treatment with DPIV inhibitors is not accompanied by significant side effects such as weight gain and hypoglycaemia.
  • pre-clinical data exist which suggest that DPIV inhibitors preserve beta-cell mass, see International Patent Application No. WO01/72290 , raising the possibility that treatment with a DPIV inhibitor would decrease the rate of decline of beta-cell function that occurs with time in type 2 diabetes.
  • the current treatment paradigm in type 2 diabetes is to commence therapy with one class of oral agent, following 'failure' of diet and exercise, with addition of a second (and later a third) class of agent only when glycaemic control is no longer adequate on the initial agent(s), i.e. the treatment comprises first-line monotherapy followed by second-line combination therapy followed by third-line combination therapy.
  • the DPIV inhibitor sitagliptin phosphate (JanuviaTM) is approved for use in the US in combination with metformin or a PPAR ⁇ agonist only when the metformin or PPAR ⁇ agonist alone, with diet and exercise, does not provide adequate glycaemic control.
  • no DPIV inhibitors are licensed for simultaneous commencement of therapy with a second class of anti-diabetic agent on initiation of oral therapy, after 'failure' of diet and exercise, in type 2 diabetes.
  • the present invention provides a novel first line, i.e. initial, combination therapy for the treatment of type 2 diabetes i.e. for the treatment of type 2 diabetes after 'failure' of diet and exercise. This method has the potential to provide greater efficacy than current monotherapy given alone without introducing any side-effect liability.
  • the present invention provides a DPIV inhibitor in combination with metformin or a thiazolidinedione as first-line combination therapy for treatment of type 2 diabetes, i.e. to be used in patients who do not have adequate glycaemic control on treatment with diet and exercise alone.
  • a method for the treatment of type 2 diabetes in a human comprises administering a combination of a DPIV inhibitor and metformin or a thiazolidinedione as first-line therapy, to a human in need thereof.
  • First-line therapy is defined as the first course of pharmaceutical treatment used against a disease, thus in the present case it represents the first pharmacological intervention to treat type 2 diabetes in a patient diagnosed as having inadequate glycaemic control.
  • a type 2 diabetic patient this will generally be a patient whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and/or exercise alone.
  • the method may be used to treat a human that has failed to achieve adequate glycaemic control using diet, weight reduction and/or exercise alone.
  • Such a patient population has not previously been treated with a first line combination therapy comprising a DPIV inhibitor and metformin or a thiazolidinedione. Type 2 diabetes is thereby treated.
  • a method for the treatment of type 2 diabetes in a human, which mammal has not previously been treated with an antidiabetic agent, e.g. metformin or a thiazolidinedione alone, comprises administering a combination of a DPIV inhibitor and metformin or a thiazolidinedione to said human.
  • an antidiabetic agent e.g. metformin or a thiazolidinedione alone
  • the invention therefore also provides a DPIV inhibitor in combination with metformin or a thiazolidinedione for the treatment of type 2 diabetes in a human, which human has not previously been treated with an antidiabetic agent, e.g. metformin or a thiazolidinedione alone.
  • an antidiabetic agent e.g. metformin or a thiazolidinedione alone.
  • the invention represents a fundamental paradigm shift away from the traditional approach of only adding additional pharmacological therapy, i.e. a second therapeutic agent, when the initial pharmacological therapy is considered to be 'failing', i.e. not providing adequate glycaemic control in the patient.
  • the invention provides significant advantages over traditional therapies for glycaemic control, including the possibility for:
  • Coadministration of the DPIV inhibitor and metformin or a thiazolidinedione includes administration of a formulation which includes both the DPIV inhibitor and metformin or a thiazolidinedione, or the essentially simultaneous, sequential or separate administration of separate formulations of the DPIV inhibitor and metformin or a thiazolidinedione.
  • the DPIV inhibitor is preferably administered in combination with metformin.
  • metformin includes any pharmaceutically acceptable salt of metformin e.g. the hydrochloride salt.
  • thiazolidinedione and the specific examples of thiazolidinediones referred to below includes any pharmaceutically acceptable salts of thiazolidinediones.
  • Suitable TZDs for use in accordance with the invention include (+)-5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione (troglitazone), 5-[4-[(1-methylcyclohexyl)methoxy]benzyl]thiazolidine-2,4-dione (ciglitazone), 5-[4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl]thiazolidine-2,4-dione (pioglitazone), 5-[(2-benzyl-2,3-dihydrobenzopyran)-5-ylmethyl)thiazolidine-2,4-dione (englitazone) and 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzy
  • Preferred TZDs are 5-[4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl]thiazolidine-2,4-dione (pioglitazone), (+)-5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione (troglitazone) and 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (rosiglitazone) and salts thereof.
  • a particularly preferred TZD is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (rosiglitazone) and pharmaceutically acceptable salts thereof.
  • DPIV inhibitors bind to DPIV and inhibit DPIV enzyme activity.
  • the DPIV inhibitor for use in the method of the invention is preferably a small molecule DPIV inhibitor.
  • DPIV inhibitor includes any pharmaceutically acceptable salts of DPIV inhibitors.
  • Examples of DPIV inhibitors include compounds disclosed in the following patent applications: WO95/15309 , WO95/29691 , WO98/18763 , WO98/19998 , WO99/25719 , WO99/38501 , WO99/46272 , WO99/61431 , WO99/62914 , WO99/67278 , WO99/67279 , WO00/34241 , WO01/34594 , WO01/40180 , WO01/55105 , WO01/52825 , WO01/68603 , WO01/72290 , WO01/81304 , WO01/81337 , WO01/96295 , WO01/97808 , WO02/02560 , WO02/08090 , WO02/14271 , WO02/30890 , WO02/30891 , WO02/38541 , WO02/51836 , WO02
  • Examples of specific DPIV inhibitors include sitagliptin, vildagliptin, saxagliptin, denagliptin and alogliptin and salts thereof.
  • a preferred DPIV inhibitor for use in the method of the invention is glutaminyl thiazolidine or a pharmaceutically acceptable salt thereof, e.g. the hydrochloride salt, see WO03/072556 .
  • Preferred combinations include the following:
  • the DPIV inhibitor and the metformin or thiazolidinedione are each administered in a pharmaceutically acceptable form, including pharmaceutically acceptable derivatives such as pharmaceutically acceptable salts, esters and solvates thereof, as appropriate of the relevant pharmaceutically active agent.
  • pharmaceutically acceptable derivatives such as pharmaceutically acceptable salts, esters and solvates thereof, as appropriate of the relevant pharmaceutically active agent.
  • the names used for the active agent may relate to a particular pharmaceutical form of the relevant active agent. It will be understood that the use of all pharmaceutically acceptable forms of the active agents per se is encompassed by this invention.
  • Pharmaceutically acceptable salts of the preferred DPIV inhibitor glutaminyl thiazolidine include acid addition salts, i.e. where the amino acid basic side chain is protonated with an inorganic or organic acid.
  • Representative organic and inorganic acids include hydrochloric, hydrobromic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, p-toulenesulfonic, cyclohexanesulfamic, salicylic, saccharinic, trifluoroacetic, sulfinic and 3,5-di-tert-butylbenzoic acid.
  • Preferred acid addition salts include the fumarate, benzoate, maleinate, oxalate, 3,5-di-tertiary-butylbenzoate, salicylate, acetate and hydrochloride salts, especially the hydrochloride salt.
  • the DPIV inhibitor and the metformin or thiazolidinedione are preferably administered orally. In particular they are preferably formulated in unit doses for administration once, twice or three times a day.
  • the DPIV inhibitor is glutaminyl thiazolidine or a salt thereof it is preferably administered two or three times a day.
  • compositions of the invention are intimately admixed with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, which carrier may take a wide variety of forms depending of the form of preparation desired for administration, e.g. oral or parenteral such as intramuscular.
  • a pharmaceutical carrier may take a wide variety of forms depending of the form of preparation desired for administration, e.g. oral or parenteral such as intramuscular.
  • any of the usual pharmaceutical media may be employed.
  • suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like;
  • suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar coated or enteric coated by standard techniques.
  • the carrier will usually comprise sterile water, through other ingredients, for example, for purposes such as aiding solubility or for preservation, may be included.
  • Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed.
  • the pharmaceutical compositions herein will contain, per dosage unit, e.g. tablet, capsule, powder, injection, teaspoonful and the like, an amount of the active agent necessary to deliver a therapeutically effective amount.
  • the dosages may be varied depending upon the requirement of the patients, the severity of the condition being treated and the compound being employed. The use of either daily administration or post-periodic dosing may be employed.
  • compositions are in unit dosage form such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, autoinjector devices or suppositories; for oral parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation.
  • a pharmaceutical carrier e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g.
  • a solid preformulation composition containing a homogeneous mixture of the active agent(s).
  • the active agent is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective dosage forms such as tablets, pills and capsules.
  • This solid preformulation composition is then subdivided into unit dosage forms of the type described above.
  • Tablets or pills can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
  • the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
  • the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release.
  • enteric layers or coatings such materials including a number of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
  • Liquid forms in which the DPIV inhibitor and the metformin or thiazolidinedione may be incorporated for administration orally or by injection include, aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
  • Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone or gelatin and the like.
  • Forms useful for parenteral administration include sterile solutions, emulsions and suspensions. Isotonic preparations which generally contain suitable preservatives are employed when intravenous administration is desired.
  • the method of treating type 2 diabetes as described herein may also be carried out using a pharmaceutical composition comprising a DPIV inhibitor, optionally in combination with metformin or a thiazolidinedione, and a pharmaceutically acceptable carrier.
  • the pharmaceutical composition may be constituted into any form suitable for the mode of administration selected.
  • Carriers include necessary and inert pharmaceutical excipients, including, but not limited to, binders, suspending agents, lubricants, flavorants, sweeteners, preservatives, dyes, and coatings.
  • compositions suitable for oral administration include solid forms, such as pills, tablets, caplets, capsules (each including immediate release, timed release and sustained release formulations), granules, and powders, and liquid forms, such as solutions, syrups, elixirs, emulsions, and suspensions.
  • the active agents can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
  • suitable binders; lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture.
  • Suitable binders include, without limitation, starch, gelatin, natural sugars such as glucose or betalactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
  • Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
  • the DPIV inhibitor and metformin or a thiazolidinedione may be administered in any of the foregoing compositions and according to dosage regimens whenever glycaemic control is required.
  • Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular active agent used, the mode of administration, the strength of the preparation, the mode of administration, and the advancement of disease condition. In addition, factors associated with the particular patient being treated, including patient age, weight, diet and time of administration, will result in the need to adjust dosages.
  • Suitable dosages, including especially unit dosages, of the active agents to be used in the method of the invention include the known dosages including unit doses for these compounds as described or referred to in reference text such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press) (for example see the 31st Edition page 341 and pages cited therein) or the above mentioned publications.
  • Suitable doses of DPIV inhibitors include those described in the relevant publications mentioned above.
  • Suitable unit doses of the preferred DPIV inhibitor glutaminyl thiazolidine are in the range 10 to 500mg, e.g. 50, 100, 200 or 300mg, which unit doses may be administered up to three times a day.
  • a suitable daily dosage of metformin is between 50 and 3000mg, for example 250, 500mg, 850mg or 1000mg.
  • the invention comprises administration of unit doses of 2 to 12 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione.
  • Suitable unit dosages of TZDs include from 100 to 800mg of troglitazone such as 200, 400, 600 or 800mg or from 5 to 50mg, including 10 to 40mg, of pioglitazone, such as 20, 30 or 40 mg and also including 15, 30 and 45mg of pioglitazone.
  • each particular active agent in any given composition can as required vary within a range of doses known to be required in respect of accepted dosage regimens for that compound. Dosages of each active agent can also be adapted as required to take into account advantageous effects of combining the agents as mentioned herein.
  • the DPIV inhibitor and metformin or a thiazolidinedione may be taken before, during or after a meal. When taken before a meal they can be taken 1 hour, preferably 30 or even 15 or 5 minutes before eating. When taken after a meal they can be taken 5, 15 or 30 minutes or even 1 hour after finishing a meal.
  • the particularly beneficial effect on glycaemic control in the treatment of type 2 diabetes provided by the combination of the invention is an improved therapeutic ratio relative to the therapeutic ratio for one compound of the combination when used alone and at a dose providing an equivalent efficacy to the combination of the invention.
  • Glycaemic control may be characterised using conventional methods, for example by measurement of a typically used index of glycaemic control such as fasting plasma glucose or glycosylated haemoglobin (HbAlc). Such indices are determined using standard methodology, for example those described in: Tuescher A, Richterich, P., Sau. med. Wschr. 101 (1971), 345 and 390 and Frank P., 'Monitoring the Diabetic Patent with Glycosolated Hemoglobin Measurements', Clinical Products 1988.
  • a typically used index of glycaemic control such as fasting plasma glucose or glycosylated haemoglobin (HbAlc).
  • HbAlc glycosylated haemoglobin
  • the dosage level of each of the active agents when used in accordance with the invention may be less than would have been required from a purely additive effect upon glycaemic control.
  • terapéuticaally effective amount means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human, being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Description

    FIELD OF THE INVENTION
  • This invention relates to a combination of a DPIV inhibitor and metformin or thiazolidinedione for use in a therapeutic method for glycaemic control, in particular a method for the treatment of type 2 diabetes.
    • BACKGROUND ART
  • Diabetes mellitus is a chronic metabolic disorder characterized by the presence of hyperglycaemia (raised blood glucose concentrations). It may be divided into four general subclasses, including i) type 1 or insulin-dependent diabetes mellitus (IDDM) (caused by beta-cell destruction and characterized by absolute insulin deficiency), ii) type 2 or non-insulin-dependent diabetes mellitus (NIDDM) (characterized by impaired insulin action and impaired insulin secretion), iii) other specific types of diabetes (associated with various identifiable clinical conditions or syndromes such as genetic defects of beta-cell function e.g. maturity-onset diabetes of the young types 1 - 3 and point mutations in mitochondrial DNA), and iv) gestational diabetes mellitus.
  • The prevalence of type 2 diabetes is high and is growing at an alarming rate. The global burden of diabetes mellitus is expected to reach 300 million by the year 2025, with more than 90% of these individuals having type 2 diabetes.
  • The predominant pathophysiological defects leading to hyperglycaemia in type 2 diabetes are impaired insulin action (insulin resistance) and impaired insulin secretion (beta-cell dysfunction). Treating hyperglycaemia is therapeutically important in diabetes mellitus in order to prevent symptoms caused by the raised blood glucose concentrations, such as polyuria (excessive urination) and polydipsia (excessive thirst), and to reduce the risk of diabetic complications. The chronic hyperglycaemia of diabetes mellitus is associated with significant, often devastating long-term complications in the eyes, kidneys, nerves and blood vessels. The largest study of pharmacotherapy in type 2 diabetes, The United Kingdom Prospective Diabetes Study (UKPDS), demonstrated that lowering blood glucose concentrations with pharmacotherapy in type 2 diabetes reduces the risk of complications. [Lancet 352:837-853, 1998]. The study showed that there was no lower threshold for the benefits of glucose lowering and that any additional glucose lowering would further reduce the risk of development of diabetic complications.
  • The UKPDS also demonstrated that an inexorable decline in beta-cell function occurs with time in type 2 diabetes [Diabetes 44:1249-1258, 1995]. This leads, in the majority of patients, to worsening of glycaemic control with time, requiring addition of more and more therapies as the disease progresses.
  • There are a number of oral agents currently available to treat type 2 diabetes. The three classes of agent which are most commonly prescribed are metformin, the sulphonylureas and the PPARγ agonist thiazolidinediones (TZDs). Metformin acts by decreasing glucose output from the liver, it is associated with gastrointestinal side-effects in many patients and has no impact on the decline in beta-cell function with time. The sulphonylureas act by increasing insulin secretion, are associated with the side effects of weight gain and hypoglycaemia (low blood glucose concentrations) and, like metformin, have no impact on the decline in beta-cell function with time (see UKPDS). The TZDs act as insulin sensitizers and, whilst they are the only class of oral agent currently licensed to treat type 2 diabetes which decreases the rate of decline of beta-cell function with time, they are associated with the side effects of weight gain and oedema.
  • It is known that DPIV inhibitors may be useful for the treatment of impaired glucose tolerance and diabetes mellitus, see International Patent Application No. WO97/40832 . Clinical data suggest that the glucose lowering that occurs in response to treatment with DPIV inhibitors is not accompanied by significant side effects such as weight gain and hypoglycaemia. In addition, pre-clinical data exist which suggest that DPIV inhibitors preserve beta-cell mass, see International Patent Application No. WO01/72290 , raising the possibility that treatment with a DPIV inhibitor would decrease the rate of decline of beta-cell function that occurs with time in type 2 diabetes.
  • The current treatment paradigm in type 2 diabetes is to commence therapy with one class of oral agent, following 'failure' of diet and exercise, with addition of a second (and later a third) class of agent only when glycaemic control is no longer adequate on the initial agent(s), i.e. the treatment comprises first-line monotherapy followed by second-line combination therapy followed by third-line combination therapy. Thus, for example, the DPIV inhibitor sitagliptin phosphate (Januvia™) is approved for use in the US in combination with metformin or a PPARγ agonist only when the metformin or PPARγ agonist alone, with diet and exercise, does not provide adequate glycaemic control. Currently, no DPIV inhibitors are licensed for simultaneous commencement of therapy with a second class of anti-diabetic agent on initiation of oral therapy, after 'failure' of diet and exercise, in type 2 diabetes.
  • There is a need to find new and improved regimens for the treatment of type 2 diabetes. The present invention provides a novel first line, i.e. initial, combination therapy for the treatment of type 2 diabetes i.e. for the treatment of type 2 diabetes after 'failure' of diet and exercise. This method has the potential to provide greater efficacy than current monotherapy given alone without introducing any side-effect liability.
    • SUMMARY OF THE INVENTION
  • The present invention provides a DPIV inhibitor in combination with metformin or a thiazolidinedione as first-line combination therapy for treatment of type 2 diabetes, i.e. to be used in patients who do not have adequate glycaemic control on treatment with diet and exercise alone.
    • DETAILED DESCRIPTION OF THE INVENTION
  • A method for the treatment of type 2 diabetes in a human, comprises administering a combination of a DPIV inhibitor and metformin or a thiazolidinedione as first-line therapy, to a human in need thereof.
  • First-line therapy is defined as the first course of pharmaceutical treatment used against a disease, thus in the present case it represents the first pharmacological intervention to treat type 2 diabetes in a patient diagnosed as having inadequate glycaemic control. In a type 2 diabetic patient this will generally be a patient whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and/or exercise alone. The method may be used to treat a human that has failed to achieve adequate glycaemic control using diet, weight reduction and/or exercise alone. Such a patient population has not previously been treated with a first line combination therapy comprising a DPIV inhibitor and metformin or a thiazolidinedione. Type 2 diabetes is thereby treated.
  • A method for the treatment of type 2 diabetes in a human, which mammal has not previously been treated with an antidiabetic agent, e.g. metformin or a thiazolidinedione alone, comprises administering a combination of a DPIV inhibitor and metformin or a thiazolidinedione to said human.
  • The invention therefore also provides a DPIV inhibitor in combination with metformin or a thiazolidinedione for the treatment of type 2 diabetes in a human, which human has not previously been treated with an antidiabetic agent, e.g. metformin or a thiazolidinedione alone.
  • The invention represents a fundamental paradigm shift away from the traditional approach of only adding additional pharmacological therapy, i.e. a second therapeutic agent, when the initial pharmacological therapy is considered to be 'failing', i.e. not providing adequate glycaemic control in the patient.
  • The invention provides significant advantages over traditional therapies for glycaemic control, including the possibility for:
    • greater blood glucose lowering than with monotherapy e.g. using metformin or a TZD alone, this is advantageous because there is no lower threshold for the benefits of glucose lowering and current agents have modest efficacy;
    • targeting of the two main pathophysiological defects in type 2 diabetes (insulin resistance and beta-cell dysfunction) simultaneously;
    • maximisation of the opportunity for early positioning in the treatment continuum of a therapy which reduces decline in beta-cell function; and/or
    • reduced risk of hypoglycaemia or weight gain.
  • Coadministration of the DPIV inhibitor and metformin or a thiazolidinedione includes administration of a formulation which includes both the DPIV inhibitor and metformin or a thiazolidinedione, or the essentially simultaneous, sequential or separate administration of separate formulations of the DPIV inhibitor and metformin or a thiazolidinedione.
  • The DPIV inhibitor is preferably administered in combination with metformin. As referred to in the present application "metformin" includes any pharmaceutically acceptable salt of metformin e.g. the hydrochloride salt.
  • As referred to in the present application "thiazolidinedione" and the specific examples of thiazolidinediones referred to below includes any pharmaceutically acceptable salts of thiazolidinediones.
  • Suitable TZDs for use in accordance with the invention include (+)-5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione (troglitazone), 5-[4-[(1-methylcyclohexyl)methoxy]benzyl]thiazolidine-2,4-dione (ciglitazone), 5-[4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl]thiazolidine-2,4-dione (pioglitazone), 5-[(2-benzyl-2,3-dihydrobenzopyran)-5-ylmethyl)thiazolidine-2,4-dione (englitazone) and 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (rosiglitazone) and pharmaceutically acceptable salts thereof.
  • Preferred TZDs are 5-[4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl]thiazolidine-2,4-dione (pioglitazone), (+)-5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione (troglitazone) and 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (rosiglitazone) and salts thereof. A particularly preferred TZD is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (rosiglitazone) and pharmaceutically acceptable salts thereof.
  • DPIV inhibitors bind to DPIV and inhibit DPIV enzyme activity. The DPIV inhibitor for use in the method of the invention is preferably a small molecule DPIV inhibitor. As referred to in the present application "DPIV inhibitor" includes any pharmaceutically acceptable salts of DPIV inhibitors.
  • Examples of DPIV inhibitors include compounds disclosed in the following patent applications: WO95/15309 , WO95/29691 , WO98/18763 , WO98/19998 , WO99/25719 , WO99/38501 , WO99/46272 , WO99/61431 , WO99/62914 , WO99/67278 , WO99/67279 , WO00/34241 , WO01/34594 , WO01/40180 , WO01/55105 , WO01/52825 , WO01/68603 , WO01/72290 , WO01/81304 , WO01/81337 , WO01/96295 , WO01/97808 , WO02/02560 , WO02/08090 , WO02/14271 , WO02/30890 , WO02/30891 , WO02/38541 , WO02/51836 , WO02/53548 , WO02/62764 , WO02/66627 , WO02/67918 , WO02/68420 , WO02/76450 , WO02/83109 , WO02/83128 , WO03/00181 , WO03/00181 , WO03/00250 , WO03/02530 , WO03/02531 , WO03/02553 , WO03/02942 , WO03/03250 , WO03/03727 , WO03/04496 , WO03/04498 , WO03/104229 , WO03/24965 , WO03/35057 , WO03/35067 , WO03/04498 , WO03/33524 , WO03/33671 , WO03/37327 , WO03/55881 , WO03/57144 , WO03/57200 , WO03/57666 , WO03/68748 , WO03/68757 , WO03/74500 , WO03/84940 , WO03/92605 , WO03/101449 , WO03/101958 , WO03/106456 , WO04/16587 , WO04/16840 , WO04/18468 , WO04/18469 , WO04/24184 , WO04/26822 , WO04/33455 , WO04/37169 , WO04/37181 , WO04/41795 , WO04/43940 , WO04/46106 , WO04/46148 , WO04/48352 , WO04/50022 , WO04/50658 , WO04/52850 , WO04/103276 , WO04/112701 , WO05/12249 , WO05/12308 , WO05/12312 , WO05/16911 , WO05/19168 , WO05/25554 , WO05/26148 , WO05/30751 , WO05/37779 , WO05/37828 , WO05/40095 , WO05/42533 , WO05/42488 , WO05/44195 , WO05/47297 , WO05/51949 , WO05/51950 , WO05/56541 , WO05/56013 , WO05/56003 , WO05/58849 , WO05/58901 , WO05/63750 , WO05/73186 , WO05/75421 , WO05/75426 , WO05/77900 , WO05/82906 , WO05/82847 , WO05/82349 , WO05/82348 , WO05/85246 , WO05/87774 , WO05/87235 , WO05/95343 , WO05/95381 , WO05/95339 , WO05/97798 , WO05/100334 , WO05/108382 , WO05/113510 , WO05/116012 , WO05/11614 , WO05/11629 , WO05/118555 , WO05/120494 , EP1245568 , EP1258476 , EP1258480 , EP1338595 , JP2002265439 and JP2003300977 .
  • Examples of specific DPIV inhibitors include sitagliptin, vildagliptin, saxagliptin, denagliptin and alogliptin and salts thereof.
  • A preferred DPIV inhibitor for use in the method of the invention is glutaminyl thiazolidine or a pharmaceutically acceptable salt thereof, e.g. the hydrochloride salt, see WO03/072556 .
  • Preferred combinations include the following:
    • glutaminyl thiazolidine, or a pharmaceutically acceptable salt thereof, and metformin;
    • glutaminyl thiazolidine, or a pharmaceutically acceptable salt thereof, and a thiazolidinedione;
    • glutaminyl thiazolidine, or a pharmaceutically acceptable salt thereof, and troglitazone, ciglitazone, pioglitazone, englitazone or rosiglitazone; and
    • glutaminyl thiazolidine, or a pharmaceutically acceptable salt thereof, and rosiglitazone.
  • Preferred embodiments of the invention thus include:
    • a combination of glutaminyl thiazolidine or a pharmaceutically acceptable salt thereof and metformin as first-line therapy for administration to a human who has failed to achieve adequate glycaemic control using diet, weight reduction and/or exercise alone for the treatment of type 2 diabetes.
    • a combination of glutaminyl thiazolidine or a pharmaceutically acceptable salt thereof and a thiazolidinedione as first-line therapy for administration to a human who has failed to achieve adequate glycaemic control using diet, weight reduction and/or exercise alone for the treatment of type 2 diabetes.
    • a combination of glutaminyl thiazolidine or a pharmaceutically acceptable salt thereof, and metformin for administration to a human who has not previously been treated with an antidiabetic agent, e.g. metformin or a thiazolidinedione alone, for the treatment of type 2 diabetes.
    • a combination of glutaminyl thiazolidine or a pharmaceutically acceptable salt thereof, and a thiazolidinedione for administration to a human who has not previously been treated with an antidiabetic agent, e.g. metformin or a thiazolidinedione alone, for the treatment of type 2 diabetes.
  • The DPIV inhibitor and the metformin or thiazolidinedione are each administered in a pharmaceutically acceptable form, including pharmaceutically acceptable derivatives such as pharmaceutically acceptable salts, esters and solvates thereof, as appropriate of the relevant pharmaceutically active agent. In certain instances herein the names used for the active agent may relate to a particular pharmaceutical form of the relevant active agent. It will be understood that the use of all pharmaceutically acceptable forms of the active agents per se is encompassed by this invention.
  • Pharmaceutically acceptable salts of the preferred DPIV inhibitor glutaminyl thiazolidine include acid addition salts, i.e. where the amino acid basic side chain is protonated with an inorganic or organic acid. Representative organic and inorganic acids include hydrochloric, hydrobromic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, p-toulenesulfonic, cyclohexanesulfamic, salicylic, saccharinic, trifluoroacetic, sulfinic and 3,5-di-tert-butylbenzoic acid. Preferred acid addition salts include the fumarate, benzoate, maleinate, oxalate, 3,5-di-tertiary-butylbenzoate, salicylate, acetate and hydrochloride salts, especially the hydrochloride salt.
  • The DPIV inhibitor and the metformin or thiazolidinedione are preferably administered orally. In particular they are preferably formulated in unit doses for administration once, twice or three times a day. When the DPIV inhibitor is glutaminyl thiazolidine or a salt thereof it is preferably administered two or three times a day.
  • To prepare the pharmaceutical compositions of the invention the active agents are intimately admixed with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, which carrier may take a wide variety of forms depending of the form of preparation desired for administration, e.g. oral or parenteral such as intramuscular. In preparing compositions in oral dosage form, any of the usual pharmaceutical media may be employed. Thus, for liquid oral preparations, such as for example, suspensions, elixirs and solutions, suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like; for solid oral preparations such as, for example, powders, capsules, gelcaps and tablets, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar coated or enteric coated by standard techniques. For parenterals, the carrier will usually comprise sterile water, through other ingredients, for example, for purposes such as aiding solubility or for preservation, may be included.
  • Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed. The pharmaceutical compositions herein will contain, per dosage unit, e.g. tablet, capsule, powder, injection, teaspoonful and the like, an amount of the active agent necessary to deliver a therapeutically effective amount. The dosages, however, may be varied depending upon the requirement of the patients, the severity of the condition being treated and the compound being employed. The use of either daily administration or post-periodic dosing may be employed.
  • Preferably these compositions are in unit dosage form such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, autoinjector devices or suppositories; for oral parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. For preparing solid compositions such as tablets, the principal active agent is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of the active agent(s). When referring to these preformulation compositions as homogeneous, it is meant that the active agent is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above.
  • Tablets or pills can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
  • Liquid forms in which the DPIV inhibitor and the metformin or thiazolidinedione may be incorporated for administration orally or by injection include, aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions, include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone or gelatin and the like. Forms useful for parenteral administration include sterile solutions, emulsions and suspensions. Isotonic preparations which generally contain suitable preservatives are employed when intravenous administration is desired.
  • The method of treating type 2 diabetes as described herein may also be carried out using a pharmaceutical composition comprising a DPIV inhibitor, optionally in combination with metformin or a thiazolidinedione, and a pharmaceutically acceptable carrier. The pharmaceutical composition may be constituted into any form suitable for the mode of administration selected. Carriers include necessary and inert pharmaceutical excipients, including, but not limited to, binders, suspending agents, lubricants, flavorants, sweeteners, preservatives, dyes, and coatings. Compositions suitable for oral administration include solid forms, such as pills, tablets, caplets, capsules (each including immediate release, timed release and sustained release formulations), granules, and powders, and liquid forms, such as solutions, syrups, elixirs, emulsions, and suspensions. For instance, for oral administration in the form of a tablet or capsule, the active agents can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders; lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include, without limitation, starch, gelatin, natural sugars such as glucose or betalactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
  • The DPIV inhibitor and metformin or a thiazolidinedione may be administered in any of the foregoing compositions and according to dosage regimens whenever glycaemic control is required. Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular active agent used, the mode of administration, the strength of the preparation, the mode of administration, and the advancement of disease condition. In addition, factors associated with the particular patient being treated, including patient age, weight, diet and time of administration, will result in the need to adjust dosages.
  • Suitable dosages, including especially unit dosages, of the active agents to be used in the method of the invention include the known dosages including unit doses for these compounds as described or referred to in reference text such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press) (for example see the 31st Edition page 341 and pages cited therein) or the above mentioned publications.
  • Suitable doses of DPIV inhibitors include those described in the relevant publications mentioned above. Suitable unit doses of the preferred DPIV inhibitor glutaminyl thiazolidine are in the range 10 to 500mg, e.g. 50, 100, 200 or 300mg, which unit doses may be administered up to three times a day.
  • A suitable daily dosage of metformin is between 50 and 3000mg, for example 250, 500mg, 850mg or 1000mg.
  • In one particular aspect the invention comprises administration of unit doses of 2 to 12 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione.
  • Suitable unit dosages of TZDs include from 100 to 800mg of troglitazone such as 200, 400, 600 or 800mg or from 5 to 50mg, including 10 to 40mg, of pioglitazone, such as 20, 30 or 40 mg and also including 15, 30 and 45mg of pioglitazone.
  • Also, the dosages of each particular active agent in any given composition can as required vary within a range of doses known to be required in respect of accepted dosage regimens for that compound. Dosages of each active agent can also be adapted as required to take into account advantageous effects of combining the agents as mentioned herein.
  • The DPIV inhibitor and metformin or a thiazolidinedione may be taken before, during or after a meal. When taken before a meal they can be taken 1 hour, preferably 30 or even 15 or 5 minutes before eating. When taken after a meal they can be taken 5, 15 or 30 minutes or even 1 hour after finishing a meal.
  • Suitably, the particularly beneficial effect on glycaemic control in the treatment of type 2 diabetes provided by the combination of the invention is an improved therapeutic ratio relative to the therapeutic ratio for one compound of the combination when used alone and at a dose providing an equivalent efficacy to the combination of the invention.
  • Glycaemic control may be characterised using conventional methods, for example by measurement of a typically used index of glycaemic control such as fasting plasma glucose or glycosylated haemoglobin (HbAlc). Such indices are determined using standard methodology, for example those described in: Tuescher A, Richterich, P., Schweiz. med. Wschr. 101 (1971), 345 and 390 and Frank P., 'Monitoring the Diabetic Patent with Glycosolated Hemoglobin Measurements', Clinical Products 1988.
  • The dosage level of each of the active agents when used in accordance with the invention may be less than would have been required from a purely additive effect upon glycaemic control.
  • The term "therapeutically effective amount" as used herein, means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human, being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.

Claims (11)

  1. A DPIV inhibitor in combination with metformin or a thiazolidinedione for use as first-line therapy for the treatment of type 2 diabetes in a human, wherein the human has not previously been treated with an antidiabetic agent
  2. A combination for use according to claim 1 wherein the human has failed to achieve adequate glycaemic control using diet, weight reduction and/or exercise alone.
  3. A combination for use according to any one of the preceding claims wherein the DPIV inhibitor and metformin or a thiazolidinedione are administered simultaneously, sequentially or separately.
  4. A combination for use according to any one of the preceding claims wherein the DPIV inhibitor and metformin or a thiazolidinedione are administered in a formulation which includes both the DPIV inhibitor and metformin or a thiazolidinedione.
  5. A combination for use according to any one of the preceding claims wherein the DPIV inhibitor and metformin or a thiazolidinedione are administered orally.
  6. A combination for use according to any one of the preceding claims wherein the DPIV inhibitor is glutaminyl thiazolidine or a pharmaceutically acceptable salt thereof.
  7. A combination for use according to any one of claims I to 5 wherein the DPIV inhibitor is selected from sitagliptin, vildagliptin, saxagliptin, denagliptin and alogliptin and pharmaceutically acceptable salts thereof.
  8. A combination for use according to any one of the preceding claims wherein the DPIV inhibitor and metformin or a thiazolidinedione are administered once, twice or three times a day.
  9. A combination for use according to any one of the preceding claims wherein DPIV inhibitor is administered in combination with metformin.
  10. A combination for use according to any one of claims 1 to 8 wherein the thiazolidinedione is troglitazone, ciglitazone, pioglitazone, englitazone or rosiglitazone.
  11. A combination for use according to claim 10 wherein the thiazolidinedione is rosiglitazone.
EP06820700.0A 2005-12-23 2006-12-22 Treatment of type 2 diabetes with a combination of dpiv inhibitor and metformin or thiazolidinedione Revoked EP1965783B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL06820700T PL1965783T3 (en) 2005-12-23 2006-12-22 Treatment of type 2 diabetes with a combination of dpiv inhibitor and metformin or thiazolidinedione
SI200631633T SI1965783T1 (en) 2005-12-23 2006-12-22 Treatment of type 2 diabetes with a combination of dpiv inhibitor and metformin or thiazolidinedione
CY20131100773T CY1114401T1 (en) 2005-12-23 2013-09-09 TYPE 2 DIABETES TREATMENT WITH A combination of DPIV inhibitor and metformin or thiazolidinedione

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0526291.0A GB0526291D0 (en) 2005-12-23 2005-12-23 Therapeutic method
PCT/GB2006/050475 WO2007072083A1 (en) 2005-12-23 2006-12-22 Treatment of type 2 diabetes with a combination of dpiv inhibitor and metformin or thiazolidinedione

Publications (2)

Publication Number Publication Date
EP1965783A1 EP1965783A1 (en) 2008-09-10
EP1965783B1 true EP1965783B1 (en) 2013-06-19

Family

ID=35841111

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06820700.0A Revoked EP1965783B1 (en) 2005-12-23 2006-12-22 Treatment of type 2 diabetes with a combination of dpiv inhibitor and metformin or thiazolidinedione

Country Status (28)

Country Link
US (3) US20100216800A1 (en)
EP (1) EP1965783B1 (en)
JP (2) JP2009520801A (en)
KR (1) KR20080080220A (en)
CN (1) CN101365434A (en)
AU (1) AU2006327974B2 (en)
BR (1) BRPI0620450A2 (en)
CA (1) CA2634379C (en)
CY (1) CY1114401T1 (en)
DK (1) DK1965783T3 (en)
EA (1) EA017084B1 (en)
ES (1) ES2427822T3 (en)
GB (1) GB0526291D0 (en)
HK (1) HK1121074A1 (en)
HR (1) HRP20130880T1 (en)
IL (1) IL192257A0 (en)
MA (1) MA30085B1 (en)
MX (1) MX2008008250A (en)
NO (1) NO20082790L (en)
NZ (1) NZ569427A (en)
PL (1) PL1965783T3 (en)
PT (1) PT1965783E (en)
RS (1) RS52942B (en)
SG (1) SG186610A1 (en)
SI (1) SI1965783T1 (en)
UA (1) UA100111C2 (en)
WO (1) WO2007072083A1 (en)
ZA (1) ZA200806200B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11103469B2 (en) 2019-09-17 2021-08-31 Novartis Ag Combination therapy

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
DE102005035891A1 (en) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as pharmaceuticals
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (en) 2006-05-04 2011-04-14 Boehringer Ingelheim Int PHARMACEUTICAL COMBINATIONS INCLUDING LINAGLIPTIN AND METMORPHINE
CA2810839A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine
NZ583346A (en) 2007-07-19 2012-02-24 Takeda Pharmaceutical Solid preparation comprising alogliptin and metformin hydrochloride
PE20091730A1 (en) 2008-04-03 2009-12-10 Boehringer Ingelheim Int FORMULATIONS INVOLVING A DPP4 INHIBITOR
BRPI0916997A2 (en) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh DPP-4 INHIBITOR AND ITS USE
UY32030A (en) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
CN102149407A (en) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BRPI0923121A2 (en) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Saline forms of organic compounds
AR074990A1 (en) 2009-01-07 2011-03-02 Boehringer Ingelheim Int TREATMENT OF DIABETES IN PATIENTS WITH AN INAPPROPRIATE GLUCEMIC CONTROL THROUGH METFORMIN THERAPY
CN107115530A (en) 2009-11-27 2017-09-01 勃林格殷格翰国际有限公司 Gene diabetes mellitus type utilizes the treatment of DPP IV inhibitor such as BI 1356
RU2533560C2 (en) * 2010-03-08 2014-11-20 Цзянсу Хэнжуй Медицин Ко., Лтд. Pharmaceutical composition for treating type 2 diabetes
KR101927068B1 (en) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 Sequential Combination Therapy by the Weight Reducing Treatment Followed by the DPP-4 Inhibitor
CN102971005A (en) 2010-06-24 2013-03-13 贝林格尔.英格海姆国际有限公司 Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
WO2013103384A1 (en) 2012-01-06 2013-07-11 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013148130A1 (en) * 2012-03-29 2013-10-03 Oklahoma Medical Research Foundation Inhibition of memapsin 1 cleavage in the treatment of diabetes
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (en) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Medical use of DPP-4 inhibitors
CA3022202A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
US20220160619A1 (en) * 2020-11-25 2022-05-26 Complete Medical Solutions, Llc Effervescent Drug Formulations

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5543396A (en) 1994-04-28 1996-08-06 Georgia Tech Research Corp. Proline phosphonate derivatives
DE122010000020I1 (en) 1996-04-25 2010-07-08 Prosidion Ltd Method for lowering the blood glucose level in mammals
AU4721897A (en) 1996-10-25 1998-05-22 Tanabe Seiyaku Co., Ltd. Tetrahydroisoquinoline derivatives
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
WO1999025719A1 (en) 1997-11-18 1999-05-27 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Novel physiologically active substance sulphostin, process for producing the same, and use thereof
CA2819705C (en) 1998-02-02 2014-07-08 Trustees Of Tufts College Method of regulating glucose metabolism, and reagents related thereto
AU3034299A (en) 1998-03-09 1999-09-27 Fondatech Benelux N.V. Serine peptidase modulators
DE19823831A1 (en) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim New pharmaceutical use of isoleucyl thiazolidide and its salts
WO1999062914A1 (en) 1998-06-05 1999-12-09 Point Therapeutics, Inc. Cyclic boroproline compounds
DE19828114A1 (en) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs of unstable inhibitors of dipeptidyl peptidase IV
DE19828113A1 (en) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs of Dipeptidyl Peptidase IV Inhibitors
CO5150173A1 (en) 1998-12-10 2002-04-29 Novartis Ag COMPOUNDS N- (REPLACED GLYCLE) -2-DIPEPTIDYL-IV PEPTIDASE INHIBITING CYANOPIRROLIDINS (DPP-IV) WHICH ARE EFFECTIVE IN THE TREATMENT OF CONDITIONS MEDIATED BY DPP-IV INHIBITION
WO2000053171A1 (en) * 1999-03-05 2000-09-14 Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
AU1916401A (en) 1999-11-12 2001-06-06 Guilford Pharmaceuticals Inc. Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors
GB9928330D0 (en) 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
ATE346613T1 (en) 2000-01-21 2006-12-15 Novartis Pharma Gmbh COMPOSITIONS CONSISTING OF DIPEPTIDYLPEPTIDASE-IV INHIBITORS AND ANTIDIABETICS
AU2001228309A1 (en) 2000-01-24 2001-08-07 Novo-Nordisk A/S N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
IL151368A0 (en) 2000-03-31 2003-04-10 Probiodrug Ag Use of a dipeptidyl peptidase iv enzyme activity effector for the production of pharmaceutical compositions
GB0010183D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
GB0010188D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
TW583185B (en) 2000-06-13 2004-04-11 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
AU2001268958B2 (en) 2000-07-04 2006-03-09 Novo Nordisk A/S Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
US20020007602A1 (en) 2000-07-21 2002-01-24 John Corcoran Intermodal container pallet
HU227882B1 (en) 2000-08-10 2012-05-29 Mitsubishi Tanabe Pharma Corp Proline derivatives and use thereof as drugs
AU9419701A (en) 2000-10-06 2002-04-22 Tanabe Seiyaku Co Aliphatic nitrogenous five-membered ring compounds
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
EP1354882A1 (en) 2000-12-27 2003-10-22 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
WO2002053548A1 (en) 2000-12-27 2002-07-11 Banyu Pharmaceutical Co.,Ltd. Benzothiazepine derivatives
HUP0400058A2 (en) 2001-02-02 2004-04-28 Takeda Chemical Industries, Ltd. Fused heterocyclic compounds, pharmaceutical compositions containing them and their use
WO2002066627A1 (en) 2001-02-16 2002-08-29 Bayer Aktiengesellschaft Regulation of human dipeptidyl peptidase 8
EA007485B1 (en) 2001-02-24 2006-10-27 Берингер Ингельхайм Фарма Гмбх Унд Ко. Кг Xanthine derivative, method for their production, pharmaceutical composition based thereon and method for their preparation
WO2002067918A1 (en) 2001-02-27 2002-09-06 Banyu Pharmaceutical Co., Ltd. Novel diallylmethylamine derivative
JP2002265439A (en) 2001-03-08 2002-09-18 Mitsubishi Pharma Corp Cyanopyrrolidine derivative and its use for medicine
ATE395912T1 (en) 2001-03-27 2008-06-15 Merck & Co Inc DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
FR2822826B1 (en) 2001-03-28 2003-05-09 Servier Lab NOVEL ALPHA-AMINO ACID SULPHONYL DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
GB0109146D0 (en) 2001-04-11 2001-05-30 Ferring Bv Treatment of type 2 diabetes
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
FR2824825B1 (en) 2001-05-15 2005-05-06 Servier Lab NOVEL ALPHA-AMINOACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US20030060494A1 (en) 2001-05-18 2003-03-27 Nobuyuki Yasuda Pharmaceutical use of N-carbamoylazole derivatives
SE523510C2 (en) 2001-05-18 2004-04-27 Jan G Faeger Method for determining the position and / or orientation of a creature in relation to an environment
ES2257555T3 (en) 2001-06-20 2006-08-01 MERCK & CO., INC. DIPEPTIDILPEPTIDASE INHIBITORS FOR THE TREATMENT OF DIABETES.
GB0115517D0 (en) 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
EP1399470A2 (en) 2001-06-27 2004-03-24 Probiodrug AG Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents
DE10150203A1 (en) 2001-10-12 2003-04-17 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitor in treatment of cancer
ATE374181T1 (en) 2001-06-27 2007-10-15 Smithkline Beecham Corp FLUORPYRROLIDINES AS DIPEPTIDYLPEPTIDASE INHIBITORS
ATE370943T1 (en) 2001-06-27 2007-09-15 Smithkline Beecham Corp FLUOROPYRROLIDINE AS DIPEPTIDYL-PEPTIDASE INHIBITORS
EP1399420B1 (en) 2001-06-27 2007-12-05 SmithKline Beecham Corporation Pyrrolidines as dipeptidyl peptidase inhibitors
US20030005443A1 (en) 2001-06-27 2003-01-02 Karin Axelsson EPG having PIP window history and sample view functionality
WO2003003250A1 (en) 2001-06-28 2003-01-09 Hywire Ltd. Range content-addressable memory
JP2005502624A (en) 2001-07-03 2005-01-27 ノボ　ノルディスク　アクティーゼルスカブ Purine derivatives inhibiting DPP-IV for the treatment of diabetes
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
AU2002331311A1 (en) 2001-09-19 2003-04-01 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
EP1572892A4 (en) 2001-10-18 2007-08-22 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
GB0125445D0 (en) 2001-10-23 2001-12-12 Ferring Bv Protease Inhibitors
GB0125446D0 (en) 2001-10-23 2001-12-12 Ferring Bv Novel anti-diabetic agents
US6861440B2 (en) 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
AU2002360732A1 (en) 2001-12-26 2003-07-24 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
US6727261B2 (en) 2001-12-27 2004-04-27 Hoffman-La Roche Inc. Pyrido[2,1-A]Isoquinoline derivatives
ATE409466T1 (en) 2002-01-11 2008-10-15 Novo Nordisk As METHOD AND COMPOSITION FOR TREATING DIABETES, HYPERTENSION, CHRONIC HEART FAILURE AND CONDITIONS ASSOCIATED WITH FLUID RETENTION
BR0307665A (en) 2002-02-13 2005-01-04 Hoffmann La Roche Compounds, process for their manufacture, pharmaceutical compositions comprising them, method for treating and / or prophylaxis of diseases associated with dpp iv and use of the compounds
CN1308311C (en) 2002-02-13 2007-04-04 霍夫曼-拉罗奇有限公司 Novel pyridine- and quinoline-derivatives
US7074798B2 (en) 2002-02-25 2006-07-11 Eisai Co., Ltd Xanthine derivative and DPPIV inhibitor
HUP0200849A2 (en) 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetyl-pyrrolidine-2-carbonitrile derivatives, pharmaceutical compositions containing them and process for producing them
EP1492777A1 (en) 2002-04-08 2005-01-05 Torrent Pharmaceuticals Ltd Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidase inhibitors
JP2003300977A (en) 2002-04-10 2003-10-21 Sumitomo Pharmaceut Co Ltd Xanthine derivative
AU2003228793B2 (en) 2002-04-30 2008-01-03 Trustees Of Tufts College Smart Pro-Drugs of Serine Protease Inhibitors
BR0311608A (en) 2002-06-04 2005-02-22 Pfizer Prod Inc Cyclically fluorinated amides as dipeptidyl peptidase iv inhibitors
WO2003101449A2 (en) 2002-06-04 2003-12-11 Pfizer Products Inc. Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof
CN100469778C (en) 2002-06-06 2009-03-18 卫材R&D管理有限公司 New fused imidazole derivative
HUP0202001A2 (en) 2002-06-14 2005-08-29 Sanofi-Aventis Azabicyclo-octane and nonane derivatives with ddp-iv inhibiting activity
AU2003254927A1 (en) 2002-08-13 2004-03-03 Bell Textile Co. Functional product and functional fine powder for use in production thereof, and method for producing functional product
TW200404796A (en) 2002-08-19 2004-04-01 Ono Pharmaceutical Co Nitrogen-containing compound
JP4233524B2 (en) 2002-08-21 2009-03-04 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 8- [3-Amino-piperidin-1-yl] -xanthine, its preparation and its use as a pharmaceutical composition
DE10238477A1 (en) 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg New purine derivatives, their production and their use as medicines
US20060039974A1 (en) 2002-09-11 2006-02-23 Takeda Pharmaceutical Company Limited Sustained release preparation
KR101072236B1 (en) 2002-09-19 2011-10-12 아보트 러보러터리즈 -- Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IVDPP-IV
WO2004033455A2 (en) 2002-10-08 2004-04-22 Novo Nordisk A/S Hemisuccinate salts of heterocyclic dpp-iv inhibitors
KR20050067418A (en) 2002-10-18 2005-07-01 머크 앤드 캄파니 인코포레이티드 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
ATE469645T1 (en) 2002-10-23 2010-06-15 Bristol Myers Squibb Co GLYCINENITRIL BASED INHIBITORS OF DIPEPTIDYLPEPTIDASE IV
WO2004041795A1 (en) 2002-10-30 2004-05-21 Guilford Pharmaceuticals Inc. Novel inhibitors of dipeptidyl peptidase iv
PL376822A1 (en) 2002-11-07 2006-01-09 Merck & Co., Inc. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004046106A1 (en) 2002-11-18 2004-06-03 Pfizer Products Inc. Dipeptidyl peptidase iv inhibiting fluorinated cyclic amides
DE10254304A1 (en) 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg New xanthine derivatives, their production and their use as medicines
AU2002952946A0 (en) 2002-11-27 2002-12-12 Fujisawa Pharmaceutical Co., Ltd. Dpp-iv inhibitor
UY28103A1 (en) 2002-12-03 2004-06-30 Boehringer Ingelheim Pharma NEW IMIDAZO-PIRIDINONAS REPLACED, ITS PREPARATION AND ITS EMPLOYMENT AS MEDICATIONS
WO2004050022A2 (en) 2002-12-04 2004-06-17 Merck & Co., Inc. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7420079B2 (en) 2002-12-09 2008-09-02 Bristol-Myers Squibb Company Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
EP1624874B1 (en) 2003-05-14 2009-11-04 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004112701A2 (en) 2003-06-17 2004-12-29 Merck & Co., Inc. Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
DE10333935A1 (en) 2003-07-25 2005-02-24 Aventis Pharma Deutschland Gmbh New bicyclic cyano-heterocycles, process for their preparation and their use as pharmaceuticals
PE20050249A1 (en) 2003-07-25 2005-06-01 Aventis Pharma Gmbh NEW CYANOPYRROLIDES AND PROCEDURE FOR THEIR PREPARATION AS MEDICINES
US20050026881A1 (en) 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
MXPA06001054A (en) 2003-07-31 2006-04-24 3M Innovative Properties Co Bioactive compositions comprising triazines.
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
CN1867560A (en) 2003-08-13 2006-11-22 武田药品工株式会社 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
WO2005019168A2 (en) 2003-08-20 2005-03-03 Pfizer Products Inc. Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors
MXPA06002127A (en) * 2003-09-02 2006-05-31 Prosidion Ltd Combination therapy for glycaemic control.
EP1697342A2 (en) 2003-09-08 2006-09-06 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP2007505121A (en) 2003-09-08 2007-03-08 武田薬品工業株式会社 Dipeptidyl peptidase inhibitor
WO2005025554A2 (en) 2003-09-09 2005-03-24 Japan Tobacco Inc. Dipeptidyl peptidase iv inhibitor
DE10348022A1 (en) 2003-10-15 2005-05-25 Imtm Gmbh New dipeptidyl peptidase IV inhibitors for the functional influence of different cells and for the treatment of immunological, inflammatory, neuronal and other diseases
GB0324236D0 (en) 2003-10-16 2003-11-19 Astrazeneca Ab Chemical compounds
TW200519105A (en) 2003-10-20 2005-06-16 Lg Life Science Ltd Novel inhibitors of DPP-IV, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
TW200528440A (en) 2003-10-31 2005-09-01 Fujisawa Pharmaceutical Co 2-cyanopyrrolidinecarboxamide compound
TW200523252A (en) 2003-10-31 2005-07-16 Takeda Pharmaceutical Pyridine compounds
CN1870990A (en) 2003-11-04 2006-11-29 默克公司 Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
PT1689757E (en) 2003-11-12 2014-12-09 Sino Med Internat Alliance Inc Heterocyclic boronic acid compounds
WO2005051949A1 (en) 2003-11-26 2005-06-09 Dainippon Sumitomo Pharma Co., Ltd. Novel condensed imidazole derivative
DE10355304A1 (en) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 8- (piperazin-1-yl) and 8 - ([1,4] diazepan-1-yl) xanthines, their preparation and their use as pharmaceuticals
EP1541143A1 (en) 2003-12-09 2005-06-15 Graffinity Pharmaceuticals Aktiengesellschaft Dpp-iv inhibitors
EP1541148A1 (en) 2003-12-09 2005-06-15 Graffinity Pharmaceuticals Aktiengesellschaft Dpp-iv inhibitors
CN1890228B (en) 2003-12-11 2011-07-20 田边三菱制药株式会社 Alpha-amino acid derivatives and use thereof as medicines
WO2005058849A1 (en) 2003-12-15 2005-06-30 Glenmark Pharmaceuticals Ltd. New dipeptidyl peptidase in inhibitors; process for their preparation and compositions containing them
DE10359098A1 (en) 2003-12-17 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 2- (piperazin-1-yl) and 2 - ([1,4] diazepan-1-yl) imidazo [4,5-d] pyridazin-4-ones, their preparation and their use as pharmaceuticals
DE10360835A1 (en) 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg New bicyclic imidazole derivatives are dipeptidylpeptidase-IV inhibitors useful to treat e.g. arthritis, obesity, allograft transplantation and calcitonin-induced osteoporosis
WO2005073186A1 (en) 2004-01-29 2005-08-11 Ono Pharmaceutical Co., Ltd. Pyrrolidine derivatives
WO2005075426A1 (en) 2004-02-03 2005-08-18 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
EP1712547B1 (en) 2004-02-05 2011-12-14 Kyorin Pharmaceutical Co., Ltd. Bicycloester derivative
AU2005219508B2 (en) 2004-02-18 2012-02-16 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthine, the production thereof and the use in the form of a DPP inhibitor
EP1717225A4 (en) 2004-02-18 2009-10-21 Kyorin Seiyaku Kk Bicyclic amide derivatives
BRPI0507972A (en) 2004-02-23 2007-07-24 Tufts College compound, pharmaceutical composition, use of a compound, method for inhibiting the proteolytic activity of a postproline cleavage enzyme and packaged pharmaceutical composition
DE102004009039A1 (en) 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8- [3-Amino-piperidin-1-yl] xanthines, their preparation and use as pharmaceuticals
US7514571B2 (en) 2004-02-27 2009-04-07 Kyorin Pharmaceutical Co., Ltd. Bicyclo derivative
KR100552043B1 (en) 2004-02-28 2006-02-20 주식회사종근당 Composition for obesity treatment comprising fumagillol derivatives
EP1593671A1 (en) 2004-03-05 2005-11-09 Graffinity Pharmaceuticals AG DPP-IV inhibitors
EP1729774A4 (en) 2004-03-09 2009-05-06 Nat Health Research Institutes Pyrrolidine compounds
DE102004012366A1 (en) 2004-03-13 2005-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Imidazopyridazinediones, their preparation and their use as medicines
CN102079743B (en) 2004-03-15 2020-08-25 武田药品工业株式会社 Dipeptidyl peptidase inhibitors
WO2005095339A1 (en) 2004-03-31 2005-10-13 Pfizer Products Inc. Dicyanopyrrolidines as dipeptidyl peptidase iv inhibitors
JP2007531780A (en) 2004-04-10 2007-11-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel 2-amino-imidazo [4,5-D] pyridazin-4-one and 2-amino-imidazo [4,5-C] pyridazin-4-one, their preparation and use as pharmaceuticals
WO2005100334A1 (en) 2004-04-14 2005-10-27 Pfizer Products Inc. Dipeptidyl peptidase-iv inhibitors
TW200604167A (en) 2004-04-27 2006-02-01 Astellas Pharma Inc Pyrrolidine derivatives
AU2005241056A1 (en) 2004-05-04 2005-11-17 Merck & Co., Inc. 1,2,4-oxadiazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
EP1598341A1 (en) 2004-05-21 2005-11-23 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft DPP-IV inhibitors
TWI415635B (en) * 2004-05-28 2013-11-21 必治妥施貴寶公司 Coated tablet formulation and method
JP2008501714A (en) 2004-06-04 2008-01-24 武田薬品工業株式会社 Dipeptidyl peptidase inhibitor
EP1604662A1 (en) 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft 1-[(3R)-Amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine-(2R)-carboxylic acid benzyl amine derivatives and related compounds as dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes mellitus

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HINKE S A ET AL: "Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 291, no. 5, 15 March 2002 (2002-03-15), pages 1302 - 1308, XP002976338, ISSN: 0006-291X, DOI: 10.1006/BBRC.2002.6607 *
KRENTZ ANDREW J ET AL: "ORAL ANTIDIABETIC AGENTS - CURRENT ROLE IN TYPE 2 DIABETES MELLITUS", DRUGS : INTERNAT. JOURNAL OF CURRENT THERAPEUTICS AND APPLIED PHARMACOLOGY REVIEWS, FEATURING EVALUATIONS ON NEW DRUGS AND DRUG THERAPY, AND DRUG LITERATURE ABSTRACTS, WOLTERS KLUWER HEALTH ADIS, AUSTRALIA, vol. 65, no. 3, 1 January 2005 (2005-01-01), pages 385 - 411, XP009085446, ISSN: 0012-6667, DOI: 10.2165/00003495-200565030-00005 *
TURNER R C ET AL: "GLYCEMIC CONTROL WITH DIET, SULFONYLUREA, METFORMIN, OR INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS PROGRESSIVE REQUIREMENT FOR MULTIPLE THERAPIES (UKPDS 49)", JAMA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, AMERICAN MEDICAL ASSOCIATION, US, vol. 281, no. 21, 2 June 1999 (1999-06-02), pages 2005 - 2012, XP008011494, ISSN: 0098-7484, DOI: 10.1001/JAMA.281.21.2005 *
YASUDA N ET AL: "Enhanced secretion of glucagon-like peptide 1 by biguanide compounds", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 298, no. 5, 15 November 2002 (2002-11-15), pages 779 - 784, XP002976340, ISSN: 0006-291X, DOI: 10.1016/S0006-291X(02)02565-2 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11103469B2 (en) 2019-09-17 2021-08-31 Novartis Ag Combination therapy

Also Published As

Publication number Publication date
HRP20130880T1 (en) 2013-10-25
US20140051734A1 (en) 2014-02-20
RS52942B (en) 2014-02-28
US20160279105A1 (en) 2016-09-29
ZA200806200B (en) 2009-04-29
CN101365434A (en) 2009-02-11
NZ569427A (en) 2011-11-25
EA200801538A1 (en) 2008-12-30
EP1965783A1 (en) 2008-09-10
AU2006327974A1 (en) 2007-06-28
KR20080080220A (en) 2008-09-02
PT1965783E (en) 2013-08-27
SI1965783T1 (en) 2013-10-30
PL1965783T3 (en) 2013-11-29
HK1121074A1 (en) 2009-04-17
AU2006327974B2 (en) 2012-10-04
IL192257A0 (en) 2009-02-11
CY1114401T1 (en) 2016-08-31
JP2009520801A (en) 2009-05-28
UA100111C2 (en) 2012-11-26
ES2427822T3 (en) 2013-11-04
EA017084B1 (en) 2012-09-28
MX2008008250A (en) 2008-11-06
CA2634379A1 (en) 2007-06-28
WO2007072083A1 (en) 2007-06-28
US20100216800A1 (en) 2010-08-26
MA30085B1 (en) 2008-12-01
NO20082790L (en) 2008-09-16
DK1965783T3 (en) 2013-08-05
GB0526291D0 (en) 2006-02-01
CA2634379C (en) 2014-05-20
JP2013227337A (en) 2013-11-07
BRPI0620450A2 (en) 2011-11-08
SG186610A1 (en) 2013-01-30

Similar Documents

Publication Publication Date Title
EP1965783B1 (en) Treatment of type 2 diabetes with a combination of dpiv inhibitor and metformin or thiazolidinedione
KR100666591B1 (en) Treatment of Diabetes with Thiazolidinedione and Metformin
US6353009B1 (en) Method for the treatment and prevention of hyperuricemia
NO314065B1 (en) Pharmaceutical composition comprising an insulin sensitivity enhancer and etbiguanide in the treatment of diabetes
KR20080028415A (en) PHARMACEUTICAL COMPOSITION CONTAINING PPARgamma; AGONIST
CA2591416A1 (en) Medicinal composition containing fbpase inhibitor
CN1263467A (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor
KR20010013845A (en) Treatment of Diabetes with Thiazolidinedione and Alpha-Glucosidase Inhibitor
US20140024687A1 (en) Combinations of Vascular Disrupting Agents with Inhibitor of Apoptosis Proteins Antagonists
PL199125B1 (en) Method of treating diabetes with thiazolydinone and sulphonylurea
US20090186818A1 (en) Therapeutic Method for Glycaemic Control
CN100431540C (en) Treatment of diabetes with thiazolidinedione and metformin
CZ20001298A3 (en) Medicament for treating hyperglycemia and pharmaceutical preparation containing insulin sensitizer
US20010034356A1 (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
CZ20001297A3 (en) Medicament for treating hyperglycemia and pharmaceutical preparation containing insulin sensitizer
NZ520542A (en) Treatment of diabetes with thiazolidinedione and metformin
JPH11255669A (en) Treating agent for hyperuricemia
MXPA99012098A (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080723

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1121074

Country of ref document: HK

17Q First examination report despatched

Effective date: 20090806

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ROYALTY PHARMA FINANCE TRUST

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ROYALTY PHARMA COLLECTION TRUST

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 617245

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130715

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602006036915

Country of ref document: DE

Effective date: 20130814

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20130812

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOHEST AG, CH

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20130880

Country of ref document: HR

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20130401679

Country of ref document: GR

Effective date: 20130920

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20130880

Country of ref document: HR

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 14737

Country of ref document: SK

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2427822

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20131104

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1121074

Country of ref document: HK

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E008385

Country of ref document: EE

Effective date: 20130909

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

26 Opposition filed

Opponent name: GENERICS (UK) LIMITED

Effective date: 20140319

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

26 Opposition filed

Opponent name: DR. THORSTEN BAUSCH

Effective date: 20140319

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602006036915

Country of ref document: DE

Effective date: 20140319

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E018979

Country of ref document: HU

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: NEW ADDRESS: HOLBEINSTRASSE 36-38, 4051 BASEL (CH)

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

PLBP Opposition withdrawn

Free format text: ORIGINAL CODE: 0009264

RDAF Communication despatched that patent is revoked

Free format text: ORIGINAL CODE: EPIDOSNREV1

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: GENERICS (UK) LIMITED

Effective date: 20140319

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

PLBP Opposition withdrawn

Free format text: ORIGINAL CODE: 0009264

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602006036915

Country of ref document: DE

Representative=s name: SCHMITT-NILSON SCHRAUD WAIBEL WOHLFROM PATENTA, DE

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20130880

Country of ref document: HR

Payment date: 20181122

Year of fee payment: 13

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20130880

Country of ref document: HR

Payment date: 20191122

Year of fee payment: 14

REG Reference to a national code

Ref country code: DE

Ref legal event code: R064

Ref document number: 602006036915

Country of ref document: DE

Ref country code: DE

Ref legal event code: R103

Ref document number: 602006036915

Country of ref document: DE

APBU Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9O

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RO

Payment date: 20191127

Year of fee payment: 14

Ref country code: FI

Payment date: 20191218

Year of fee payment: 14

Ref country code: SK

Payment date: 20191205

Year of fee payment: 14

Ref country code: SE

Payment date: 20191217

Year of fee payment: 14

Ref country code: PT

Payment date: 20191126

Year of fee payment: 14

Ref country code: MC

Payment date: 20191213

Year of fee payment: 14

Ref country code: CZ

Payment date: 20191206

Year of fee payment: 14

Ref country code: IE

Payment date: 20191212

Year of fee payment: 14

Ref country code: NL

Payment date: 20191218

Year of fee payment: 14

Ref country code: BG

Payment date: 20191220

Year of fee payment: 14

Ref country code: LT

Payment date: 20191126

Year of fee payment: 14

RDAG Patent revoked

Free format text: ORIGINAL CODE: 0009271

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT REVOKED

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20191218

Year of fee payment: 14

Ref country code: FR

Payment date: 20191216

Year of fee payment: 14

Ref country code: BE

Payment date: 20191218

Year of fee payment: 14

Ref country code: DK

Payment date: 20191217

Year of fee payment: 14

Ref country code: GR

Payment date: 20191219

Year of fee payment: 14

Ref country code: PL

Payment date: 20191126

Year of fee payment: 14

Ref country code: EE

Payment date: 20191220

Year of fee payment: 14

REG Reference to a national code

Ref country code: FI

Ref legal event code: MGE

27W Patent revoked

Effective date: 20200108

GBPR Gb: patent revoked under art. 102 of the ep convention designating the uk as contracting state

Effective date: 20200108

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20191218

Year of fee payment: 14

Ref country code: AT

Payment date: 20191219

Year of fee payment: 14

REG Reference to a national code

Ref country code: SK

Ref legal event code: MC4A

Ref document number: E 14737

Country of ref document: SK

Effective date: 20200108

REG Reference to a national code

Ref country code: GR

Ref legal event code: NF

Ref document number: 20130401679

Country of ref document: GR

Effective date: 20200415

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20200102

Year of fee payment: 14

Ref country code: IT

Payment date: 20191223

Year of fee payment: 14

Ref country code: GB

Payment date: 20191218

Year of fee payment: 14

REG Reference to a national code

Ref country code: EE

Ref legal event code: MF4A

Ref document number: E008385

Country of ref document: EE

Effective date: 20200310

REG Reference to a national code

Ref country code: HR

Ref legal event code: PNEV

Ref document number: P20130880

Country of ref document: HR

REG Reference to a national code

Ref country code: AT

Ref legal event code: MA03

Ref document number: 617245

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200108

REG Reference to a national code

Ref country code: SE

Ref legal event code: ECNC

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20191219

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20201205

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LV

Payment date: 20201221

Year of fee payment: 15

Ref country code: IS

Payment date: 20201221

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20211201

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20221129

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20221205

Year of fee payment: 17

REG Reference to a national code

Ref country code: SI

Ref legal event code: NC00

Effective date: 20231011